Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
2.

Neuroradiological and clinical features in ophthalmoplegia.

Weidauer S, Hofmann C, Wagner M, Hattingen E.

Neuroradiology. 2019 Feb 12. doi: 10.1007/s00234-019-02183-3. [Epub ahead of print] Review.

PMID:
30747268
3.

Retinoencephalopathy with occipital lobe epilepsy in an OPA-1 mutation carrier.

Nass RD, Hansen N, Quesada C, Rüber T, Kornblum C, Zsurka G, Hermann P, Becker A, Gärtner F, Hattingen E, Block W, Steidl E, Elger CE, Surges R, Kunz WS.

Seizure. 2019 Jan 30;66:1-3. doi: 10.1016/j.seizure.2019.01.029. [Epub ahead of print] No abstract available.

PMID:
30738307
4.

The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility, and a revised proposal.

Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rudà R, Furtner J, Hempel JM, Postma TJ, Roth P, Snijders TJ, Winkler F, Winklerhofer S, Castellano A, Hattingen E, Capellades J, Gorlia T, van den Bent M, Wen PY, Bendzus M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group (BTG) Central Nervous System (CNS) Metastases Committee and the EORTC BTG Imaging Committee.

Neuro Oncol. 2019 Jan 23. doi: 10.1093/neuonc/noz024. [Epub ahead of print]

PMID:
30715514
5.

Influence of pregnancy on glioma patients.

Forster MT, Baumgarten P, Gessler F, Maurer G, Senft C, Hattingen E, Seifert V, Harter PN, Franz K.

Acta Neurochir (Wien). 2019 Mar;161(3):535-543. doi: 10.1007/s00701-019-03823-6. Epub 2019 Jan 29.

PMID:
30693372
6.

Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients.

Voss M, Franz K, Steinbach JP, Fokas E, Forster MT, Filipski K, Hattingen E, Wagner M, Breuer S.

J Neurooncol. 2019 Mar;142(1):161-169. doi: 10.1007/s11060-018-03076-w. Epub 2019 Jan 2.

PMID:
30604393
7.

Successful mechanical thrombectomy in stroke with thrombolysis-associated intracerebral hemorrhage-a case report.

Weller JM, Hattingen E, Petzold GC, Bode FJ.

J Stroke Cerebrovasc Dis. 2019 Feb;28(2):285-287. doi: 10.1016/j.jstrokecerebrovasdis.2018.09.045. Epub 2018 Oct 24.

PMID:
30529220
8.

Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with 1 H-MRS.

Wenger KJ, Hattingen E, Harter PN, Richter C, Franz K, Steinbach JP, Bähr O, Pilatus U.

NMR Biomed. 2019 Jan;32(1):e4027. doi: 10.1002/nbm.4027. Epub 2018 Nov 20.

PMID:
30457203
9.

Systematic evaluation of stroke thrombectomy in clinical practice: The German Stroke Registry Endovascular Treatment.

Alegiani AC, Dorn F, Herzberg M, Wollenweber FA, Kellert L, Siebert E, Nolte CH, von Rennenberg R, Hattingen E, Petzold GC, Bode FJ, Pfeilschifter W, Schäfer JH, Wagner M, Röther J, Eckert B, Kraft P, Pham M, Boeckh-Behrens T, Wunderlich S, Bernkopf K, Reich A, Wiesmann M, Mpotsaris A, Psychogios M, Liman J, Maier I, Berrouschot J, Bormann A, Limmroth V, Spreer J, Petersen M, Krause L, Lowens S, Kraemer C, Zweynert S, Lange KS, Thonke S, Kastrup A, Papanagiotou P, Alber B, Braun M, Fiehler J, Gerloff C, Dichgans M, Thomalla G.

Int J Stroke. 2018 Oct 22:1747493018806199. doi: 10.1177/1747493018806199. [Epub ahead of print] Erratum in: Int J Stroke. 2018 Dec 17;:1747493018816194.

PMID:
30346260
10.

Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features.

Andreiuolo F, Varlet P, Tauziède-Espariat A, Jünger ST, Dörner E, Dreschmann V, Kuchelmeister K, Waha A, Haberler C, Slavc I, Corbacioglu S, Riemenschneider MJ, Leipold A, Rüdiger T, Körholz D, Acker T, Russo A, Faber J, Sommer C, Armbrust S, Rose M, Erdlenbruch B, Hans VH, Bernbeck B, Schneider D, Lorenzen J, Ebinger M, Handgretinger R, Neumann M, van Buiren M, Prinz M, Roganovic J, Jakovcevic A, Park SH, Grill J, Puget S, Messing-Jünger M, Reinhard H, Bergmann M, Hattingen E, Pietsch T.

Brain Pathol. 2019 Mar;29(2):205-216. doi: 10.1111/bpa.12659. Epub 2018 Nov 11.

PMID:
30246434
11.

Evidence for peri-ictal blood-brain barrier dysfunction in patients with epilepsy.

Rüber T, David B, Lüchters G, Nass RD, Friedman A, Surges R, Stöcker T, Weber B, Deichmann R, Schlaug G, Hattingen E, Elger CE.

Brain. 2018 Oct 1;141(10):2952-2965. doi: 10.1093/brain/awy242.

PMID:
30239618
12.

Cerebrovascular Reactivity during Prolonged Breath-Hold in Experienced Freedivers.

Keil VC, Eichhorn L, Mutsaerts HJMM, Träber F, Block W, Mädler B, van de Ven K, Siero JCW, MacIntosh BJ, Petr J, Fimmers R, Schild HH, Hattingen E.

AJNR Am J Neuroradiol. 2018 Oct;39(10):1839-1847. doi: 10.3174/ajnr.A5790. Epub 2018 Sep 20.

PMID:
30237299
13.

Limbic Encephalitis in Patients with Epilepsy-is Quantitative MRI Diagnostic?

Schievelkamp AH, Jurcoane A, Rüber T, Ernst L, Müller A, Mädler B, Schild HH, Hattingen E.

Clin Neuroradiol. 2018 Jul 16. doi: 10.1007/s00062-018-0705-1. [Epub ahead of print]

PMID:
30014154
14.

Mirror movements and blepharoclonus as novel phenomena in hereditary diffuse leukoencephalopathy with spheroids.

Traschütz A, Hattingen E, Klockgether T, Paus S.

Parkinsonism Relat Disord. 2019 Jan;58:83-84. doi: 10.1016/j.parkreldis.2018.07.001. Epub 2018 Jul 2. No abstract available.

PMID:
29983329
15.

Teaching NeuroImages: Distinct visual anosognosia after serial lesions of Meyer loop and the lateral geniculate body.

Traschütz A, Hattingen E, Klockgether T.

Neurology. 2018 Jul 3;91(1):e94-e95. doi: 10.1212/WNL.0000000000005744. No abstract available.

PMID:
29967211
16.

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28.

PMID:
29808316
17.

Tractography Verified by Intraoperative Magnetic Resonance Imaging and Subcortical Stimulation During Tumor Resection Near the Corticospinal Tract.

Münnich T, Klein J, Hattingen E, Noack A, Herrmann E, Seifert V, Senft C, Forster MT.

Oper Neurosurg (Hagerstown). 2019 Feb 1;16(2):197-210. doi: 10.1093/ons/opy062.

PMID:
29669002
18.

The ERICA Score: An MR Imaging-based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease.

Enkirch SJ, Traschütz A, Müller A, Widmann CN, Gielen GH, Heneka MT, Jurcoane A, Schild HH, Hattingen E.

Radiology. 2018 Jul;288(1):226-333. doi: 10.1148/radiol.2018171888. Epub 2018 Mar 7.

PMID:
29514015
19.

New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact.

Blasel S, Vorwerk R, Kiyose M, Mittelbronn M, Brunnberg U, Ackermann H, Voss M, Harter PN, Hattingen E.

J Neurol. 2018 Mar;265(3):647-658. doi: 10.1007/s00415-018-8737-7. Epub 2018 Jan 30.

PMID:
29383512
20.

Hippocampal "gliosis only" on MR imaging represents a distinct entity in epilepsy patients.

Hattingen E, Enkirch SJ, Jurcoane A, Kruse M, Delev D, Grote A, Becker A.

Neuroradiology. 2018 Feb;60(2):161-168. doi: 10.1007/s00234-017-1939-3. Epub 2017 Oct 30.

PMID:
29085967
21.

Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P.

Neuro Oncol. 2018 Feb 19;20(3):400-410. doi: 10.1093/neuonc/nox155.

22.

In vivo Metabolic Profiles as Determined by 31P and short TE 1H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas.

Wenger KJ, Hattingen E, Franz K, Steinbach J, Bähr O, Pilatus U.

Clin Neuroradiol. 2019 Mar;29(1):27-36. doi: 10.1007/s00062-017-0630-8. Epub 2017 Oct 5.

PMID:
28983683
23.

Effects of aerobic exercise on brain metabolism and grey matter volume in older adults: results of the randomised controlled SMART trial.

Matura S, Fleckenstein J, Deichmann R, Engeroff T, Füzéki E, Hattingen E, Hellweg R, Lienerth B, Pilatus U, Schwarz S, Tesky VA, Vogt L, Banzer W, Pantel J.

Transl Psychiatry. 2017 Jul 18;7(7):e1172. doi: 10.1038/tp.2017.135.

24.

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients.

Hattingen E, Müller A, Jurcoane A, Mädler B, Ditter P, Schild H, Herrlinger U, Glas M, Kebir S.

Oncotarget. 2017 Jun 27;8(32):53542-53551. doi: 10.18632/oncotarget.18612. eCollection 2017 Aug 8.

25.

Video-EEG findings in acute bithalamic-midbrain ischemia.

Rácz A, Paus S, Hattingen E, Elger CE, Surges R.

J Neurol Sci. 2017 Sep 15;380:16-18. doi: 10.1016/j.jns.2017.06.041. Epub 2017 Jun 27. No abstract available.

PMID:
28870558
26.

Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.

Keil VC, Warmuth-Metz M, Reh C, Enkirch SJ, Reinert C, Beier D, Jones DTW, Pietsch T, Schild HH, Hattingen E, Hau P.

AJNR Am J Neuroradiol. 2017 Oct;38(10):1892-1898. doi: 10.3174/ajnr.A5313. Epub 2017 Aug 10.

27.

Brain relaxometry after macrocyclic Gd-based contrast agent.

Müller A, Jurcoane A, Mädler B, Ditter P, Schild H, Hattingen E.

Clin Neuroradiol. 2017 Dec;27(4):459-468. doi: 10.1007/s00062-017-0608-6. Epub 2017 Jul 24.

PMID:
28741075
28.

Clinical and Imaging Presentation of a Patient with Beta-Propeller Protein-Associated Neurodegeneration, a Rare and Sporadic form of Neurodegeneration with Brain Iron Accumulation (NBIA).

Hattingen E, Handke N, Cremer K, Hoffjan S, Kukuk GM.

Clin Neuroradiol. 2017 Dec;27(4):481-483. doi: 10.1007/s00062-017-0605-9. Epub 2017 Jun 22.

PMID:
28643035
29.

[Interventional radiology in the head and neck region].

Mayer C, Hattingen E, Schild H, Bootz F, Schröck A.

HNO. 2017 Jun;65(6):482-489. doi: 10.1007/s00106-017-0354-8. Review. German.

PMID:
28451716
30.

Effects of arterial input function selection on kinetic parameters in brain dynamic contrast-enhanced MRI.

Keil VC, Mädler B, Gieseke J, Fimmers R, Hattingen E, Schild HH, Hadizadeh DR.

Magn Reson Imaging. 2017 Jul;40:83-90. doi: 10.1016/j.mri.2017.04.006. Epub 2017 Apr 21.

PMID:
28438713
31.

Advances in neuro-oncology imaging.

Langen KJ, Galldiks N, Hattingen E, Shah NJ.

Nat Rev Neurol. 2017 May;13(5):279-289. doi: 10.1038/nrneurol.2017.44. Epub 2017 Apr 7. Review.

PMID:
28387340
32.

[Magnetic resonance spectroscopy of brain tumors].

Ditter P, Hattingen E.

Radiologe. 2017 Jun;57(6):450-458. doi: 10.1007/s00117-017-0241-z. German.

PMID:
28331947
33.

[Clinical magnetic resonance imaging : Frequent incidental cerebral findings].

Müller A, Ditter P, Weidauer S, Schild HH, Hattingen E.

Radiologe. 2017 Apr;57(4):251-262. doi: 10.1007/s00117-017-0229-8. Review. German.

PMID:
28280860
34.

O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.

Heinzel A, Müller D, Yekta-Michael SS, Ceccon G, Langen KJ, Mottaghy FM, Wiesmann M, Kocher M, Hattingen E, Galldiks N.

Neuro Oncol. 2017 Sep 1;19(9):1271-1278. doi: 10.1093/neuonc/now310.

35.

Intracellular pH measured by 31 P-MR-spectroscopy might predict site of progression in recurrent glioblastoma under antiangiogenic therapy.

Wenger KJ, Hattingen E, Franz K, Steinbach JP, Bähr O, Pilatus U.

J Magn Reson Imaging. 2017 Oct;46(4):1200-1208. doi: 10.1002/jmri.25619. Epub 2017 Feb 6.

PMID:
28165649
36.

Manual MRI morphometry in Parkinsonian syndromes.

Möller L, Kassubek J, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Pinkhardt EH, Respondek G, Stamelou M, Möller F, Schnitzler A, Oertel WH, Knake S, Huppertz HJ, Höglinger GU.

Mov Disord. 2017 May;32(5):778-782. doi: 10.1002/mds.26921. Epub 2017 Feb 2.

PMID:
28150443
37.

Expanded phenotype and hippocampal involvement in a novel compound heterozygosity of adult PLA2G6 associated neurodegeneration (PARK14).

Michelis JP, Hattingen E, Gaertner FC, Minnerop M, Träber F, Biskup S, Klockgether T, Paus S.

Parkinsonism Relat Disord. 2017 Apr;37:111-113. doi: 10.1016/j.parkreldis.2017.01.005. Epub 2017 Jan 10. No abstract available.

PMID:
28094106
38.

Mesial temporal lobe epilepsy associated with KCNT1 mutation.

Hansen N, Widman G, Hattingen E, Elger CE, Kunz WS.

Seizure. 2017 Feb;45:181-183. doi: 10.1016/j.seizure.2016.12.018. Epub 2016 Dec 26. No abstract available.

39.

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.

Steidl E, Pilatus U, Hattingen E, Steinbach JP, Zanella F, Ronellenfitsch MW, Bähr O.

PLoS One. 2016 Dec 29;11(12):e0168113. doi: 10.1371/journal.pone.0168113. eCollection 2016.

40.

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.

Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M.

Oncotarget. 2017 Jan 31;8(5):8294-8304. doi: 10.18632/oncotarget.14166.

41.

Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.

Müller A, Jurcoane A, Kebir S, Ditter P, Schrader F, Herrlinger U, Tzaridis T, Mädler B, Schild HH, Glas M, Hattingen E.

Cancer Med. 2017 Jan;6(1):89-99. doi: 10.1002/cam4.966. Epub 2016 Nov 28.

42.

Wernicke encephalopathy: SWI detects petechial hemorrhages in mammillary bodies in vivo.

Hattingen E, Beyle A, Müller A, Klockgether T, Kornblum C.

Neurology. 2016 Nov 1;87(18):1956-1957. No abstract available.

PMID:
27799475
43.

Combining rheology and MRI: Imaging healthy and tumorous brains based on mechanical properties.

Kofahl AL, Theilenberg S, Bindl J, Ulucay D, Wild J, Napiletzki S, Schu-Schätter B, Vohlen A, Pintea B, Finsterbusch J, Hattingen E, Urbach C, Maier K.

Magn Reson Med. 2017 Sep;78(3):930-940. doi: 10.1002/mrm.26477. Epub 2016 Oct 3.

PMID:
27699841
44.

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.

Kebir S, Rauschenbach L, Galldiks N, Schlaak M, Hattingen E, Landsberg J, Bundschuh RA, Langen KJ, Scheffler B, Herrlinger U, Glas M.

Neuro Oncol. 2016 Oct;18(10):1462-4. doi: 10.1093/neuonc/now154. Epub 2016 Sep 2. No abstract available.

45.

T2-Imaging to Assess Cerebral Oxygen Extraction Fraction in Carotid Occlusive Disease: Influence of Cerebral Autoregulation and Cerebral Blood Volume.

Seiler A, Deichmann R, Pfeilschifter W, Hattingen E, Singer OC, Wagner M.

PLoS One. 2016 Aug 25;11(8):e0161408. doi: 10.1371/journal.pone.0161408. eCollection 2016. Erratum in: PLoS One. 2016 Oct 12;11(10 ):e0164749.

46.

Spectroscopic Characterization of Gliosarcomas-Do They Differ From Glioblastomas and Metastases?

Raab P, Pilatus U, Hattingen E, Franz K, Hermann E, Zanella FE, Lanfermann H.

J Comput Assist Tomogr. 2016 Sep-Oct;40(5):815-9. doi: 10.1097/RCT.0000000000000419.

PMID:
27560009
47.

Comparison of two quantitative proton density mapping methods in multiple sclerosis.

Gracien RM, Reitz SC, Wagner M, Mayer C, Volz S, Hof SM, Fleischer V, Droby A, Steinmetz H, Groppa S, Hattingen E, Klein JC, Deichmann R.

MAGMA. 2017 Feb;30(1):75-83. doi: 10.1007/s10334-016-0585-9. Epub 2016 Aug 20.

PMID:
27544270
48.

The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis.

Gracien RM, Jurcoane A, Wagner M, Reitz SC, Mayer C, Volz S, Hof SM, Fleischer V, Droby A, Steinmetz H, Zipp F, Hattingen E, Deichmann R, Klein JC.

PLoS One. 2016 Aug 11;11(8):e0161036. doi: 10.1371/journal.pone.0161036. eCollection 2016.

49.

Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification.

Huppertz HJ, Möller L, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Respondek G, Stamelou M, Schnitzler A, Pinkhardt EH, Oertel WH, Knake S, Kassubek J, Höglinger GU.

Mov Disord. 2016 Oct;31(10):1506-1517. doi: 10.1002/mds.26715.

PMID:
27452874
50.

Intratumoral Concentrations and Effects of Orally Administered Micellar Curcuminoids in Glioblastoma Patients.

Dützmann S, Schiborr C, Kocher A, Pilatus U, Hattingen E, Weissenberger J, Geßler F, Quick-Weller J, Franz K, Seifert V, Frank J, Senft C.

Nutr Cancer. 2016 Aug-Sep;68(6):943-8. doi: 10.1080/01635581.2016.1187281. Epub 2016 Jun 24.

PMID:
27340742

Supplemental Content

Loading ...
Support Center